Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genfit SA

www.genfit.com

Latest From Genfit SA

Madrigal Cements Case For Hepatic Fat Reduction, Other NASH Benefits With MGL-3196

Madrigal’s selective THR beta agonist continues to demonstrate hepatic fat-lowering abilities in 36-week data, along with lipid-lowering characteristics. The company hopes to initiate a Phase III study in early 2019.

Liver & Hepatic Clinical Trials

Pfizer/Novartis Collaboration Brings Combined Strength To NASH Development

Combination therapy is expected to prevail in NASH. Pfizer and Novartis, while trailing smaller companies, are studying their candidates together in hopes of hitting on a winning combo for the multi-factorial disease.

Deals Research & Development

Poxel Adds To NASH Pipeline With Novel Single-Isomer Pioglitazone

Some ground-breaking chemistry has been used to produce a single isomer of pioglitazone, which has been acquired by France's Poxel to evaluate in NASH, adding to its portfolio of potential metabolic disease therapies.

 

Deals Metabolic Disorders

As Gilead Seeks New CEO, Second Quarter Shows Stability

Yescarta continued its growth trajectory, the HIV franchise showed solid sales growth and the hepatitis C franchise stayed steady – plus Gilead could jump to the head of the line in NASH.

Sales & Earnings Launches
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Hepatic (Liver)
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Genfit SA
  • Senior Management
  • Jean-Francois Mouney, Chmn. & CEO
    Nathalie Huitorel, EVP, CFO
    Dean Hum, PhD, SVP, CSO
    Sophie Mégnien , MD, CMO
  • Contact Info
  • Genfit SA
    Phone: (33) 3 20 16 40 00
    885 Ave. Eugene Avinee
    Parc Eurasante
    Loos, 59120
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register